Nor­we­gian biotech con­cludes 's­trate­gic' re­view with a re­verse merg­er

A lit­tle Nor­we­gian biotech an­nounced the end of its jour­ney Thurs­day in a re­verse merg­er, rough­ly three months af­ter an­nounc­ing it would es­sen­tial­ly sell it­self for parts.

Nordic Nanovec­tor will be swal­lowed by an­oth­er biotech based out of Nor­way, APIM Ther­a­peu­tics, the com­pa­nies said Thurs­day. When all is said and done, APIM share­hold­ers will own 76% of the com­bined com­pa­ny, which will un­veil a new name at a lat­er date, while Nordic Nanovec­tor share­hold­ers will have 24%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER